Yiyu Dong is Associate Director at WuXi Advanced Therapies. He has twenty years of dedicated experience in viral vector and cell line development. At WuXi ATU, he specializes in leading and developing high producing single clonal cell line and scalable lenti and AAV suspension platforms. His prime objective is to develop robust and cost-effective viral vector production process for clinical and commercial manufacturing. Prior to WuXi ATU, Yiyu Dong held positions in industry and academia with a focus on discovering and developing new platforms and targets for human diseases. He conducted translational medicine study at Memorial Sloan Kettering Cancer Center and published 30 peer-reviewed papers. Yiyu Dong holds a PhD from a joint program between Peking University and Yale University
